Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes.

Trial Profile

Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Liraglutide (Primary) ; Metformin
  • Indications Coronary artery disease; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms AddHope2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Oct 2016 Results assessing the effect of liraglutide on heart rate and heart rate variability over 12 weeks published in the Diabetes Care.
    • 21 Feb 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top